Safety and Efficacy of Imatinib in Combination With Artemether-Lumefantrine for Uncomplicated Malaria

This study is investigating an innovative approach to treating uncomplicated malaria by adding a drug called Imatinib to the current standard of care, Artemether + Lumefantrine (AL). The researchers hope this combination, known as ALIM, will clear infections faster and stop the spread of drug-resistant parasites that are becoming a major threat in Africa

NCT Number	NCT07559370
Lead Sponsor	Victoria Biomedical Research Institute Collaborators: Purdue University
Conditions	Malaria (Plasmodium Falciparum)
Enrollment	1,116 participants
Start Date	2026-01-20
Primary Completion	2027-06-30 (estimated)
Study Completion	2027-06-30 (estimated)
Updated on ClinicalTrials.gov	2026-06-29